HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Lumos Pharma (NASDAQ:LUMO) and maintains a $28 price target.
June 22, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Lumos Pharma and maintains a $28 price target.
The reiterated Buy rating and maintained $28 price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for Lumos Pharma. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100